Table 2.

Demographic and clinical features in 88 IBD-SpA patients compared with 176 controls.

FeatureIBD-SpAOverall SpAPsAASNr-axSpAp
N (%) of patients
  Overall8817697 (55.1)47 (26.7)32 (18.2)
  UC29 (33)
  CD59 (67)
  IBD + psoriasis14 (16)
  UC + psoriasis3 (13.7)
  CD + psoriasis11 (18.6)
Age, yrs, mean ± SD
  Overall47.66 ± 15.0946.35 ± 24.8852 ± 10.4238 ± 9.2134 ± 8.430.650
  UC51.07 ± 11.46
  CD45.67 ± 17.05
B27+, n (%)10 (11.3)70 (39.8)14 (14.4)43 (91.4)13 (40.6)< 0.001
  Axial7 (70)
  Mixed3 (30)
AxSpA, n (%)46 (52)88 (50)9 (9.2)47 (100)32 (100)0.828
  UC15 (52)
  CD31 (52.5)
Overall peripheral SpA, n (%)29 (33)62 (35)62 (64)000.819
  Oligoarticular26 (90)41 (66)41 (66)00
  Polyarticular3 (10)21 (34)21 (34)00
Mixed, n (%)13 (15)24 (14)24 (25)000.950
Disease duration, mos
  Overall60.05 ± 54.6643.21 ± 28.3463.25 ± 14.6567.33 ± 24.1623.26 ± 4.150.001
  UC76.28 ± 49.87< 0.001
  CD51.98 ± 55.440.116
Dactylitis, n (%)
  Overall4 (4.5)30 (17.4)22 (22.6)4 (8.5)4 (12.5)0.008
  UC1/29 (3.4)
  CD3/59 (5.1)
  IBD/psoriasis+3/14 (21.4)0.960
  IBD/psoriasis-negative1/74 (1.3)0.001
Enthesitis, n (%)
  Overall16 (18.1)78 (44.3)55 (56.7)11 (23.4)12 (37.5)< 0.001
  UC2 (6.9)< 0.001
  CD14 (23.7)0.008
  IBD/psoriasis+7 (50)0.895
  IBD/psoriasis-negative9 (12.1)< 0.001
Anterior uveitis, n (%)
  Overall3 (3.4)26 (14.7)11 (11.3)11 (23.4)4 (11.4)0.010
  B27+2 (66.6)19/26 (73)4/11 (36.3)9/11 (81.8)2/4 (50)0.655
  UC1 (3.4)0.169
  CD2 (3.3)0.035
  IBD/psoriasis+00.253
  IBD/psoriasis-negative3 (4.0)0.028
Followup, mos96.23 ± 12.4101.11 ± 34.220.456
  • IBD: inflammatory bowel disease; SpA: spondyloarthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; axSpA: axial SpA; nr-axSpA: nonradiographic axSpA; UC: ulcerative colitis; CD: Crohn disease.